ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom

Novo Nordisk's semaglutide franchise has taken off in a big way. Type 2 diabetes med Ozempic smashed the blockbuster barrier in 2019, the same year the company launched its oral option, Rybelsus. Now, the Danish diabetes major is touting data on a higher-dose prospect.